Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

Chng, W.j., Dispenzieri, A., Chim, C.s., Fonseca, R., Goldschmidt, H., Lentzsch, S., et al. (2014). IMWG consensus on risk stratification in multiple myeloma. LEUKEMIA, 28, 269-277 [10.1038/leu.2013.247].

IMWG consensus on risk stratification in multiple myeloma.

CAVO, MICHELE;ZAMAGNI, ELENA;
2014

Abstract

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.
2014
Chng, W.j., Dispenzieri, A., Chim, C.s., Fonseca, R., Goldschmidt, H., Lentzsch, S., et al. (2014). IMWG consensus on risk stratification in multiple myeloma. LEUKEMIA, 28, 269-277 [10.1038/leu.2013.247].
Chng, Wj; Dispenzieri, A; Chim, Cs; Fonseca, R; Goldschmidt, H; Lentzsch, S; Munshi, N; Palumbo, A; Miguel, Js; Sonneveld, P; Cavo, M; Usmani, S; Duri...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/385069
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 221
  • Scopus 500
  • ???jsp.display-item.citation.isi??? 453
social impact